FDA Greenlights First Drug for ESR1-Mutated Breast Cancer
(MedPage Today) -- The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | HER2 | International Medicine & Public Health | Women